- Home
- INVE vs CUE Comparison
INVE vs CUE Comparison
Compare INVE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | CUE |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 49.6M |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | INVE | CUE |
|---|---|---|
| Price | $3.70 | $0.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $5.50 | $3.00 |
| AVG Volume (30 Days) | 38.0K | ★ 1.5M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,015,000.00 | $7,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $0.23 |
| 52 Week High | $4.07 | $1.75 |
Technical Indicators
Market Signals| Indicator | INVE | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 39.25 |
| Support Level | $3.23 | $0.23 |
| Resistance Level | $3.70 | $0.33 |
| Average True Range (ATR) | 0.19 | 0.05 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 65.67 | 39.65 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.